Cargando…

Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo

SIMPLE SUMMARY: The clinical management for aggressive meningiomas remains challenging due to the lack of systemic treatment options. Receptor tyrosine kinases (RTKs) are frequently overexpressed in meningiomas and are associated with poor patient survival. In this study, we evaluated the clinically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Tao, Cao, Junguo, Alaa Eddine, Montadar, Moustafa, Mahmoud, Mock, Andreas, Erkut, Cihan, Abdollahi, Amir, Warta, Rolf, Unterberg, Andreas, Herold-Mende, Christel, Jungwirth, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657092/ https://www.ncbi.nlm.nih.gov/pubmed/34885009 http://dx.doi.org/10.3390/cancers13235898

Ejemplares similares

Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT
por: Jungwirth, Gerhard, et al.
Publicado: (2019)

The Antiepileptic Drug Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase Mutant Glioma Stem-like Cells
por: Dao Trong, Philip, et al.
Publicado: (2023)

Large-Scale Drug Screening in Patient-Derived IDH(mut) Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents
por: Dao Trong, Philip, et al.
Publicado: (2020)

Identification of KIF11 as a Novel Target in Meningioma
por: Jungwirth, Gerhard, et al.
Publicado: (2019)

Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma
por: Jungk, Christine, et al.
Publicado: (2019)

Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy
por: Schnabel, Elena, et al.
Publicado: (2021)

MetaboDiff: an R package for differential metabolomic analysis
por: Mock, Andreas, et al.
Publicado: (2018)

Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma
por: Jungk, Christine, et al.
Publicado: (2019)

Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma
por: Makarevic, Anastasia, et al.
Publicado: (2020)

Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
por: Dao Trong, Philip, et al.
Publicado: (2018)

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone
por: Jungk, Christine, et al.
Publicado: (2016)

Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma
por: Dunn, Jemma, et al.
Publicado: (2020)

Organerhalt: Entscheidungskriterien für Patienten mit T3-Larynxkarzinom
por: Dyckhoff, Gerhard, et al.
Publicado: (2022)

Larynxorganerhalt bis zum T4‑Larynxkarzinom?
por: Dyckhoff, Gerhard, et al.
Publicado: (2022)

Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma
por: Dyckhoff, Gerhard, et al.
Publicado: (2022)

Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade
por: Schmidt, Melissa, et al.
Publicado: (2016)

Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients
por: Dyckhoff, Gerhard, et al.
Publicado: (2021)

Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study
por: Dyckhoff, Gerhard, et al.
Publicado: (2021)

An Observational Cohort Study on 194 Supraglottic Cancer Patients: Implications for Laser Surgery and Adjuvant Treatment
por: Dyckhoff, Gerhard, et al.
Publicado: (2021)

Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis
por: Jungk, Christine, et al.
Publicado: (2016)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas
por: Dogan, Helin, et al.
Publicado: (2022)

Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma
por: Warta, Rolf, et al.
Publicado: (2014)

Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients
por: Mock, Andreas, et al.
Publicado: (2015)

Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
por: Tan, Fiona H, et al.
Publicado: (2019)

Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib
por: Corallo, Diana, et al.
Publicado: (2020)

Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib
por: Arai, Hiroyuki, et al.
Publicado: (2023)

Transcriptome profiling for precision cancer medicine using shallow nanopore cDNA sequencing
por: Mock, Andreas, et al.
Publicado: (2023)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients
por: Jungk, Christine, et al.
Publicado: (2016)

Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score
por: Dao Trong, Philip, et al.
Publicado: (2023)

Ponatinib‐induced ichthyosiform eruption
por: Kluger, Nicolas, et al.
Publicado: (2021)

mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma
por: Nazim, Uddin Md., et al.
Publicado: (2022)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS
por: José Cuenca Zamora, Ernesto, et al.
Publicado: (2023)

The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients
por: Schmoch, Thomas, et al.
Publicado: (2020)

Eruptive melanocytic nevi associated with ponatinib
por: Devred, Inès, et al.
Publicado: (2018)

Ponatinib-Induced Cerebrovascular Accident (CVA)
por: Azad, Farhan, et al.
Publicado: (2022)

Reengineering Ponatinib to Minimize Cardiovascular Toxicity
por: Hnatiuk, Anna P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ivurb4ahe4f2js2si8437b77mu